Lilly invests in partnership to fight NCDs
INDIANAPOLIS — Drug maker Eli Lilly is investing $30 million in a partnership that will address noncommunicable diseases, also known as chronic diseases.
The Lilly NCD Partnership is committed to fight the rising burden of noncommunicable diseases in developing nations over the next five years, the drug maker said. The first phase of the partnership will focus on improving diabetes care in targeted communities in Brazil, India, Mexico and South Africa.
Chronic diseases disproportionately affect the economically disadvantaged, with 80% of all NCD deaths occurring in low- and middle-income countries, Lilly said.
"Noncommunicable diseases are afflicting nations, communities and families around the world, with the most vulnerable bearing most of the burden," Lilly chairman, president and CEO John Lechleiter said. "We believe we have a responsibility — and are uniquely positioned — to assist in the global fight against these diseases. In partnership with leading health organizations, Lilly will contribute its deep expertise and the company’s broad research capabilities to help find solutions for these pressing societal needs."
The Lilly NCD Partnership, the drug maker said, complement the Lilly MDR-TB Partnership, a program the company launched in 2003 to help address multidrug resistant tuberculosis.
Duracell teams up with wireless charger company Powermat
BETHEL, Conn., and NEW YORK — Procter & Gamble’s Duracell brand announced a joint venture with wireless charger company Powermat.
As part of the strategic alliance between Duracell and Powermat, the companies will deliver best-in-class wireless power solutions. Additionally, P&G also expects to make an equity investment in Powermat.
The joint venture is expected to commence next year, the companies said.
"Several decades ago, Duracell was a pioneer in a new revolutionary product category, alkaline roundcell batteries," Duracell president Stassi Anastassov said. "Today, it is a multibillion dollar category. In a not too distant future, we expect wireless power solutions to eliminate the hassle of multiple cords and chargers, creating a major growth opportunity. Innovation to create new solutions that touch and improve people’s lives is what P&G-Duracell are all about. The JV between Duracell and Powermat puts us in the driver-seat for this disruptive category creation."
Lupin launches generic epilepsy drug
BALTIMORE — The Food and Drug Administration has approved a generic drug for epilepsy made by Lupin Pharmaceuticals, the drug maker said.
Lupin announced the approval and launch of levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.
The drug is a generic version of UCB’s Keppra XR, which had sales of about $161 million during the 12-month period ended in June, according to IMS Health.